MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers July 10, 2021 Results from a head-to-head Phase 3 study, evaluating the immune response of MenQuadfi® to serogroup C, one of the main serogroups of invasive meningococcal disease (IMD), compared to Nimenrix® (quadrivalent ACWY vaccine) and NeisVac-C® (monovalent C vaccine) in healthy toddlers, were presented today in an oral session at the 2021 European Congress of Clinical Microbiology and Infectious Disease.
New Data from the Phase 3 HELP Study Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.